Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

ere adjudicated by a blinded, independent central adjudication committee. The study was not powered to show a dose response with PRT054021 or efficacy of PRT054021 versus enoxaparin.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a twenty hour pharmacodynamic half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function. PRT054021 is expected to enter Phase III clinical development in the first half of 2008.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/22/2014)... Pa. , Oct. 22, 2014  With ... their animal health medications, a Global Pharmaceutical and ... Antares serialization technology and turnkey solution to protect ... - http://photos.prnewswire.com/prnh/20141021/153438 Photo ... product that was serialized and aggregated by the ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... Oct. 22, 2014 Sanomedics International Holdings, Inc. ... by Global Research & Data Services, demand for thermometers ... 2014 through 2018, as demand for more accurate digital ... is the world,s largest market for thermometers, and one ... is Sanomedics International Holdings, Inc. Sanomedics International ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... of abuse by intimate partners have significantly higher health ... of such abuse, according to a study conducted at ... higher costs and utilization continued long after the abuse ... of Washington (UW), and the Harborview Injury Prevention and ...
... how some passengers describe it.// , They ... were infected with a stomach flu-causing bug; norovirus aboard the ... This virus causes a contagious gastric illness, gastroenteritis that leaves ... , The liner’s owner Cunard Line notified the ...
... that neurologists believe will help in the management of epilepsy. ... New York carried out a study that showed that some ... occur. The findings were published in Neurology, the scientific journal ... Haut. ,Haut's team studied 71 adult patients ...
... and Forests has called for an action plan and ... National Workshop// on ‘Human - Leopard Conflict Management’ here ... need to have a re-look at our existing strategies ... one of the challenging issues facing wildlife managers in ...
... Parliament's health committee is all set to tighten the ... ,Three days of public hearing starting on Jan 23, ... organizations will make submissions before the committee. ... and the sponsorship of sports and other popular events ...
... (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important ... diabetics in the// December 22, 2006, Journal of ... time help researchers to identify potential targets for ... fully eliminate, the body's overproduction of glucose. ...
Cached Medicine News:Health News:Health Care Costs - Significant for Abused Women 2Health News:When Epilepsy Patients Play Soothsayers 2Health News:VBI Provides Potential Targets to Diabetes Therapeutics 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: